摘要
目的:探究前列腺癌组织delta-样配体3(DLL3)、激活转录因子6(ATF6)的表达及其与临床病理参数和预后的关系。方法:选取2022年2月至2023年5月本院收治的92例前列腺癌患者作为研究对象。采用免疫组织化学法检测前列腺癌组织和癌旁组织DLL3、ATF6的表达情况;对患者进行为期1年的随访,详细记录其随访结果,根据生存情况将患者分为死亡组与生存组;Cox多因素回归分析前列腺癌患者预后的影响因素;Kaplan-Meier法分析前列腺癌组织DLL3、ATF6表达情况与患者预后的关系。结果:DLL3在前列腺癌组织中阳性表达占78.26%,ATF6阳性表达占69.57%;DLL3在癌旁正常组织中阳性表达占18.48%,ATF6阳性表达占16.30%。DLL3、ATF6表达水平在癌组织与癌旁正常组织中差异具有统计学意义(P<0.05)。DLL3、ATF6在发生肌层浸润、TNM分期Ⅲ+Ⅳ期和发生远处转移的癌组织中具有更高的阳性表达率(P<0.05);前列腺癌患者的预后独立危险因素为肌层浸润、TNM分期Ⅲ+Ⅳ期、远处转移、DLL3(阳性)和ATF6(阳性)(P<0.05);前列腺癌组织DLL3阴性表达患者1年生存率(90.00%,18/20)高于DLL3阳性表达患者(65.28%,47/72)(χ^(2)=4.323,P=0.038);前列腺癌组织ATF6阴性表达患者1年生存率(89.29%,25/28)高于ATF6阳性表达患者(62.50%,40/64)(χ^(2)=6.275,P=0.012)。结论:DLL3、ATF6表达水平升高会造成前列腺癌患者病情恶化及预后情况较差。
Objective:To investigate the relationship between the expression of delta like ligand 3(DLL3)and activated transcription factor 6(ATF6)in prostate cancer tissue and clinical pathological parameters and prognosis.Methods:From February 2022 to May 2023,92 prostate cancer patients admitted to our hospital were regarded as subjects.Immunohistochemistry was applied to detect the expression of DLL3 and ATF6 in prostate cancer tissues and adjacent tissues.Follow up the patients for a period of 1 year,their follow-up results were recorded in detail,and patients were divided into a death group and a survival group based on their survival status.Cox multivariate regression was applied to analyze the factors influencing the prognosis of prostate cancer patients.The relationship between the expression of DLL3 and ATF6 in prostate cancer tissue and patient prognosis was analyzed using Kaplan-Meier method.Results:DLL3 was positively expressed in 78.26%of prostate cancer tissues,while ATF6 was positively expressed in 69.57%.DLL3 was positively expressed in 18.48%of normal tissues adjacent to the cancer,and ATF6 was positively expressed in 16.30%.The expression levels of the two were obviously different between cancer tissues and normal tissues adjacent to cancer(P<0.05).DLL3 and ATF6 had higher positive expression rates in cancer tissues with muscle infiltration,TNM stageⅢ+Ⅳ,and distant metastasis(P<0.05).The independent prognostic risk factors for prostate cancer patients included muscle infiltration,TNM stageⅢ+Ⅳ,distant metastasis,DLL3(positive),and ATF6(positive)(P<0.05).The one-year survival rate of patients with negative expression of DLL3 in prostate cancer tissue(90.00%,18/20)was higher than that of patients with positive expression of DLL3(65.28%,47/72)(χ^(2)=4.323,P=0.038).The one-year survival rate of patients with negative expression of ATF6 in prostate cancer tissue(89.29%,25/28)was higher than that of patients with positive expression of ATF6(62.50%,40/64)(χ^(2)=6.275,P=0.012).Conclusion:Elevated expression levels of DLL3 and ATF6 can lead to worsening of the condition and poor prognosis in prostate cancer patients.
作者
许佳佳
马凰斌
邢素倩
宋立党
张曼
陈娜
杜国望
颉亮
XU Jiajia;MA Huangbin;XING Suqian;SONG Lidang;ZHANG Man;CHEN Na;DU Guowang;JIE Liang(Department of Reproductive Medicine,Cangzhou People's Hospital,Cangzhou 061000,China;Department of Urology,Cangzhou People's Hospital,Cangzhou 061000,China)
出处
《东南大学学报(医学版)》
2025年第4期563-568,共6页
Journal of Southeast University(Medical Science Edition)
基金
河北省医学科学研究课题计划资助项目(20240629)。
关键词
前列腺癌
delta-样配体3
激活转录因子6
临床病理参数
预后
prostate cancer
delta-like ligand 3
activating transcription factor 6
clinical pathological parameters
prognosis
